Close Menu

More articles about Sample Prep

TC agreed with a judge who said that 10x's older GEM microfluidic chips infringed Bio-Rad patents, but that the firm's new Next GEM chips did not.

The firm did an initial close of its Series A financing round and will pursue additional investments during Q1 2020 when the round is anticipated to close.

The financing was led by HealthQuest Capital, with participation from 5AM Ventures and RareCyte founder Ron Seubert, and follows a $30 million round in 2017.

Perceptive Advisors led the round, joined by new and existing investors. ArcherDx will use the proceeds to launch a companion diagnostic and expand globally.

The partners will combine the capabilities of S2's Singulator instrument for solid tissue preparation and Dolomite Bio's Nadia single-cell sample prep platform.

The new method, called sci-Plex, combines nuclear hashing and improved single-cell combinatorial indexing RNA-seq to profile the transcriptional response of single cells.

CUTseq uses enzyme-based fragmentation and in vitro transcription to barcode DNA, saving money when preparing 1,000 samples or more.

A regional court said certain 10x Genomics' products, including older GEM chips and some Chromium instruments, infringed a "utility model," similar to a patent.

The firm also recently released the results of collaborations with Admera Health and RareCyte that used its multiplex PCR-based target enrichment technology.

The Chromium Connect, designed for pharma workflows and other high-volume customers, is one of several products coming out of 10x's R&D pipeline.

Due out in December, the Magnis automated library prep instrument is meant to be an affordable and easy way for researchers to use Agilent's SureSelect kits.

In its first quarter as a public company, the single-cell analysis firm reported $61.2 million in total revenues, beating Wall Street expectations.

MGI Tech will market Pillar Biosciences' Onco/Reveal NGS panels alongside its high-throughput, automated library prep systems outside the US.

The approval allows the company to directly market and sell the CTC technology to labs and other institutions to develop and implement IVD tests.

The firm's tool combines enzymatic and mechanical disruption to produce viable and accurate products for downstream single-cell applications. 

Under the non-exclusive agreement, the firms will make Twist's portfolio of NGS target enrichment products available for MGI's sequencing platforms.

The Hayward, California-based firm aims to tailor its NX One sample prep platform to isolate and detect cancer stem cells in urothelial cancer of the bladder.

The partners will integrate Genialis' gene expression analysis software with Thermo Fisher's Invitrogen Collibri Stranded RNA Library Prep kits.

MGI hopes to ship the sequencer, one of several products it unveiled at the International Conference on Genomics, to early-access partners in early 2020.

Illumina officials discussed several issues with investors, including the new Qiagen partnership, while at ASHG the firm introduced reagent kit upgrades.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.